4Dmedical stock: Q1 revenue jumps 66% as sites reach 724
Published on 10/30/2026 at 19:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSQ1 Growth Across Markets
- 4DMedical reported stronger first-quarter activity as scan volumes and its global site base expanded.
- New healthcare agreements support the company's expansion in the United States and Europe.
- Execution across its imaging portfolio remains the key focus for investors after the quarterly update.
4DMedical reported a strong start to fiscal 2027 in its quarterly activity report released on Wednesday, October 28. According to StockLight, quarterly revenue rose 66 percent to AUD 2.3 million, while scans increased 61 percent to 119,672.
The global installed base reached 724 sites. The update also highlighted a five-year agreement with a major US Veterans Affairs healthcare network for COPD detection using LDAi, as well as a German lung-screening win involving Curagita. Those developments broaden the commercial reach of 4DMedical's respiratory-imaging platform beyond its existing clinical relationships.
Commercial Scale Takes Priority
4DMedical develops advanced diagnostic imaging software for respiratory medicine. Its XV Technology and Imbio platforms are designed to provide non-invasive insights into lung function, giving hospitals and imaging networks additional tools for diagnosis and treatment planning.
For investors, the quarterly report puts the emphasis on translating higher scan volumes and a larger site footprint into sustained commercial adoption. The US contract and European screening deployment provide concrete expansion channels, while the rising number of scans offers an operating measure to watch in coming quarters.
4DMedical stock traded at 1.52 euros on Lang & Schwarz at 6:59 p.m. CET on Friday, October 30, 2026. Investors can follow the real-time quote of 4DMedical stock.
4DMedical stock at a glance
- Company: 4DMedical Limited
- ISIN: AU0000095416
- Home exchange: ASX
- Real-time quote: 1.52 euros on Lang & Schwarz, October 30, 2026, 6:59 p.m. CET
- Previous Lang & Schwarz quote: 2.07 euros
- Quarterly revenue: AUD 2.3 million in Q1 FY27
- Quarterly scans: 119,672
- Global sites: 724
Australian equities provide the relevant market backdrop for investors following the S&P/ASX 200.
More updates on the company are available in more news and analyses on 4DMedical stock.
